Combination Treatment with Rituximab and Belimumab in Shrinking Lung Syndrome in Systemic Lupus Erythematosus.

International Journal of Rheumatic DiseasesVolume 27, Issue 3 e15110 LETTER TO THE EDITOR Combination treatment with rituximab and belimumab in shrinking lung syndrome in systemic lupus erythematosus Adriana C. Esteves, Corresponding Author Adriana C. Esteves [email protected] orcid.org/0000-0001-6853-7670 Rheumatology Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal Correspondence Adriana C. Esteves, Centro Hospitalar e Universitário de Coimbra, EPE, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. Email: [email protected]Search for more papers by this authorBeatriz Mendes, Beatriz Mendes Rheumatology Department, Unidade Local de Saúde de Coimbra, Coimbra, PortugalSearch for more papers by this authorHelena Assunção, Helena Assunção Rheumatology Department, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal Rheumatology Department, Unidade Local de Saúde do Nordeste, Bragança, PortugalSearch for more papers by this authorLuís S. Inês, Luís S. Inês Rheumatology Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal School of Health Sciences, Universidade da Beira Interior, Covilhã, PortugalSearch for more papers by this author Adriana C. Esteves, Corresponding Author Adriana C. Esteves [email protected] orcid.org/0000-0001-6853-7670 Rheumatology Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal Correspondence Adriana C. Esteves, Centro Hospitalar e Universitário de Coimbra, EPE, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. Email: [email protected]Search for more papers by this authorBeatriz Mendes, Beatriz Mendes Rheumatology Department, Unidade Local de Saúde de Coimbra, Coimbra, PortugalSearch for more papers by this authorHelena Assunção, Helena Assunção Rheumatology Department, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal Rheumatology Department, Unidade Local de Saúde do Nordeste, Bragança, PortugalSearch for more papers by this authorLuís S. Inês, Luís S. Inês Rheumatology Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal School of Health Sciences, Universidade da Beira Interior, Covilhã, PortugalSearch for more papers by this author First published: 07 March 2024 https://doi.org/10.1111/1756-185X.15110Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. CONFLICT OF INTEREST STATEMENT The authors have declared no conflicts of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Saraiva L, Cunha RN, Jesus D, et al. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study. Rheumatology (Oxford). 2023. doi:10.1093/rheumatology/kead353. Online ahead of print. 10.1093/rheumatology/kead353 Web of Science®Google Scholar 2Assunção H, Jesus D, Larosa M, et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford). 2022; 61(8): 3309-3316. doi:10.1093/rheumatology/keab895 10.1093/rheumatology/keab895 CASPubMedWeb of Science®Google Scholar 3Shin JI, Lee KH, Park S, et al. Systemic lupus erythematosus and lung involvement: a comprehensive review. J Clin Med. 2022; 11(22): 6714. doi:10.3390/jcm11226714 10.3390/jcm11226714 CASPubMedWeb of Science®Google Scholar 4Jesus D, Larosa M, Henriques C, et al. Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis. 2021; 80(12): 1568-1574. doi:10.1136/annrheumdis-2021-220363 10.1136/annrheumdis-2021-220363 CASPubMedWeb of Science®Google Scholar 5Colquhoun M, Akram S. Shrinking Lung Syndrome. StatPearls. StatPearls Publishing; 2023. Google Scholar 6Almajed MR, Obri MS, Mahmood S, Demertzis ZD. Shrinking lung syndrome in a young female: a rare pulmonary manifestation of systemic lupus erythematosus. Cureus. 2022; 14(4):e24320. doi:10.7759/cureus.24320 10.7759/cureus.24320 PubMedWeb of Science®Google Scholar 7Goswami RP, Mondal S, Lahiri D, et al. Shrinking lung syndrome in systemic lupus erythematosus successfully treated with rituximab. QJM. 2016; 109(9): 617-618. doi:10.1093/qjmed/hcw093 10.1093/qjmed/hcw093 CASPubMedGoogle Scholar 8DeCoste C, Mateos-Corral D, Lang B. Shrinking lung syndrome treated with rituximab in pediatric systemic lupus erythematosus: a case report and review of the literature. Pediatr Rheumatol Online J. 2021; 19(1): 7. doi:10.1186/s12969-020-00491-0 10.1186/s12969-020-00491-0 PubMedWeb of Science®Google Scholar 9Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019; 9(3):e025687. doi:10.1136/bmjopen-2018-025687 10.1136/bmjopen-2018-025687 PubMedWeb of Science®Google Scholar 10Jones A, Muller P, Dore CJ, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019; 9(12):e032569. doi:10.1136/bmjopen-2019-032569 10.1136/bmjopen-2019-032569 PubMedWeb of Science®Google Scholar 11Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [published correction appears in arthritis Rheumatol. 2021 Dec;73(12):2356]. Arthritis Rheumatol. 2021; 73(1): 121-131. doi:10.1002/art.41466 10.1002/art.41466 CASPubMedWeb of Science®Google Scholar Volume27, Issue3March 2024e15110 ReferencesRelatedInformation